Showing results (551-560 of 782) with videos related to
Sort By:
Pageof 79
British Journal of Haematology|May 30, 2012
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium studyAndrzej J Jakubowiak, Paul G Richardson, Todd Zimmerman, et al.Blood|May 5, 2005
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.Proceedings of the National Academy of Sciences of the United States of America|January 11, 2007
WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP)Miguel A de la Fuente, Yoji Sasahara, Marco Calamito, et al.Cancer Research|July 9, 2009
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Douglas W McMillin, Melissa Ooi, Jake Delmore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.Leukemia|October 9, 2019
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myelomaGang An, Yuting Yan, Yan Xu, et al.British Journal of Haematology|January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin, Jake Delmore, Joseph Negri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.Cell Chemical Biology|October 24, 2017
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7Ilaria Lamberto, Xiaoxi Liu, Hyuk-Soo Seo, et al.Oncogene|June 9, 2005
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, et al.Pageof 79